BGN and juvenile idiopathic arthritis: Regarding the assessment of biglycan, plasma concentrations of this proteoglycan did not differ significantly (p > 0.05) between healthy children and those with JIA, including children both untreated (TB) and treated with DMARDs before biological therapy (T0) (Table 1).